Effects of additional inhaled tiotropium in relapsing polychondritis with airway involvement

Effects of additional inhaled tiotropium in relapsing polychondritis with airway involvement - Inhaled Tiotropium in RP

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006950

Enrollment

Registered

2011-12-26

Start date

2011-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsing polychondritis

Interventions

To record subjective symptoms, pulmonary function, airway diameter and dimension 3 months before, at baseline and 3 months following tiotropium

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Fulfill the McAdam or Damiani and Levine diagnosis criteria. To clarify airway chondritis using biopsy, MRI or ultrasonography 2) Airway involvement confirmed by CT 3) Respiratory symptom 4) Stable treatment for 4 weeks.

Exclusion criteria

Exclusion criteria: 1) Glaucoma or benign prostatic hypertrophy 2) Use of other anticholinergic agents within 1 month 3) Refused informed consent 4) Pregnant, possibly pregnant, or lactating patients. 5) Severe lung cancer, COPD and pneumonia except for bronchial asthma patients. 6) Patients judged inappropriate by the doctor in charge. 7) Current smokers.

Design outcomes

Primary

Measure	Time frame
1. Dyspnea score (MMRC, Borg scale, visual analog score) 2. Change in FEV1 3. Airway diameter and dimension using MDCT	—

Countries

Japan

Contacts

Public ContactHiroshi Handa

St. Marianna University School of Medicine Respiratory and Infectious Diseases, Department of Internal Medicine

044-977-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026